Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEVEL: 177Lu-edotreotide vs Everolimus in Lung and Thymus Neuroendocrine Tumors
NCT05918302Phase 3Recruiting
- Sponsor
- Spanish Group of Neuroendocrine Tumors
- Start
- Oct 2023
- Primary completion
- Mar 2029
- Modality
- Peptide-Drug Conjugates
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of lutetium Lu 177-edotreotide in Neuroendocrine Neoplasm (NEN) (2 arms), sponsored by Spanish Group of Neuroendocrine Tumors. Primary endpoint: Progression-Free Survival. Started Oct 2023; status: recruiting.
02
Drugs
lutetium Lu 177-edotreotide
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT05918302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05918302.